financetom
Business
financetom
/
Business
/
Bri-Chem Q1 Adjusted Loss Narrows Significantly
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bri-Chem Q1 Adjusted Loss Narrows Significantly
May 26, 2025 9:28 AM

07:34 AM EDT, 05/16/2025 (MT Newswires) -- Bri-Chem ( BRYFF ) on Friday reported that its first-quarter adjusted net loss narrowed significantly.

The oilfield chemical distribution and blending company said the adjusted net loss, which does not include most one-item items, improved to $618,000 or $0.02 per share, from $1.8 million, or $0.07 per share, in the prior year period.

Quarterly sales fell 7%, to $20 million. The decrease is primarily due to decreased U.S. drilling activity, driven by a lower average rig count, the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Keysight Technologies Completes Acquisition of Spirent Communications PLC
Keysight Technologies Completes Acquisition of Spirent Communications PLC
Oct 15, 2025
SANTA ROSA, Calif. & LONDON--(BUSINESS WIRE)-- Keysight Technologies, Inc. ( KEYS ) , today announced it has completed its acquisition of Spirent Communications plc ( SPNUF ) . Today marks a milestone for Keysight ( KEYS ) as we officially welcome Spirent into our company. By combining Keysight’s leading design, emulation, and test expertise with Spirent’s strengths in satellite emulation,...
BRIEF-Abra Group Announces Intended Confidential Submission Of Draft Registration Statement For Proposed IPO
BRIEF-Abra Group Announces Intended Confidential Submission Of Draft Registration Statement For Proposed IPO
Oct 15, 2025
Oct 15 (Reuters) - Abra Group: * ABRA GROUP ANNOUNCES INTENDED CONFIDENTIAL SUBMISSION OF DRAFT REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING Source text: ...
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Oct 15, 2025
Eli Lilly and Co ( LLY ) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels. LLY is gathering positive momentum. See what is happening here. ACHIEVE-2, the second head-to-head trial, evaluated orforglipron versus AstraZeneca Plc’s Farxiga (dapagliflozin) in adults with type 2 diabetes inadequately controlled on commonly...
ASP Isotopes Stock Tumbles After Company Announces Public Offering
ASP Isotopes Stock Tumbles After Company Announces Public Offering
Oct 15, 2025
ASP Isotopes Inc ( ASPI ) shares are trading lower on Wednesday after the company announced the pricing of an underwritten public offering. ASPI is encountering selling pressure. See what is happening here. What Happened: ASP Isotopes ( ASPI ), an advanced materials company specializing in isotope production technology for various industries, priced an underwritten public offering of approximately 17.17 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved